Nav: Home

New imaging technique shows effectiveness of cystic fibrosis drug

April 12, 2017

COLUMBIA, Mo. (April 12, 2017) -- According to the Cystic Fibrosis Foundation, more than 30,000 Americans are living with the disorder. It currently has no cure, though a drug approved by the Food and Drug Administration treats the underlying cause of the disease. However, the drug's effectiveness for each individual is unknown. Researchers from the University of Missouri School of Medicine have developed an imaging technique using a specific form of helium to measure the drug's effectiveness. Researchers hope the finding could lead to improved therapies for cystic fibrosis and other lung conditions.

"People with cystic fibrosis have an imbalance of salt in their bodies caused by the defective CFTR protein," said Talissa Altes, M.D., chair of the Department of Radiology at the MU School of Medicine and lead author of the study. "The drug 'ivacaftor' targets this defective protein, but to what extent it is successful is not well understood. Our study sought to use a new way of imaging the lung to understand how well the drug is working in patients with a specific gene mutation known as G551D-CFTR."

Cystic fibrosis causes the buildup of thick mucus that can clog airways and lead to dangerous infections. Although advances in the understanding and treatment of cystic fibrosis have allowed many people with the condition to live into their early 40s, many patients with cystic fibrosis die of respiratory failure.

Currently, lung function is measured using a test known as spirometry, in which patients blow through a tube; their progress is tracked over time. However, this method is not well suited for pediatric patients because it requires concentration, controlled breathing and cooperation with the spirometry technician. Computerized tomography, or CT scans, can be used, but they provide structural images of the lungs and do not show gas or airflow.

Altes and her team decided to use a specific form of helium, helium-3, as a harmless contrast agent in conjunction with magnetic resonance imaging (MRI) to visualize lung function. The study was conducted in two parts. In part one, eight patients were given either ivacaftor or a placebo for four weeks to measure short-term effectiveness. In part two, nine patients received ivacaftor for 48 weeks to determine long-term effectiveness. After each phase, patients performed a spirometry test and underwent MRI imaging using hyperpolarized helium.

"We found that after using ivacaftor, patients experienced a dramatic increase in lung improvement in both the short and long term," Altes said. "On an MRI, a healthy lung should look completely white when helium-3 is used as a contrast agent. Conversely, areas that are not white indicate poor ventilation. That's the beauty of this technique -- it's very obvious if the drug is working or not."

With more study, Altes hopes to apply helium-3 MRI to younger children or babies with impaired lung function or other respiratory diseases.

"More drugs are under development to treat cystic fibrosis and other lung conditions, and improved imaging techniques are needed to test their effectiveness," Altes said. "The importance of this technique is that it may well be a cost-effective tool to aid in the development of these drugs. However, it also can help patients know which medications may work best for their unique conditions."
-end-
The study, "Use of Hyperpolarized Helium-3 MRI to Assess Response to Ivacaftor Treatment in Patients with Cystic Fibrosis," recently was published in the Journal of Cystic Fibrosis. Research reported in this publication was supported by Vertex Pharmaceuticals Incorporated, the manufacturer of ivacaftor, the Hartwell Foundation and Siemens Healthcare. Two study authors, Mac Johnson and Meredith Fidler, are employees of Vertex Pharmaceuticals Incorporated and may own stock or stock options in the company. One study author, Martyn Botfield, is a former employee of Vertex Pharmaceuticals Incorporated and may own stock or stock options in the company. The content is solely the responsibility of the authors and does not necessarily represent the official views of the funding agencies.

About the MU School of Medicine

The MU School of Medicine has improved health, education and research in Missouri and beyond for more than 165 years. MU physicians treat patients from every county in the state, and more Missouri physicians received their medical degrees from MU than from any other university. For more information, visit http://medicine.missouri.edu/.

University of Missouri-Columbia

Related Cystic Fibrosis Articles:

Cystic fibrosis alters the structure of mucus in airways
Cystic fibrosis (CF) alters the structure of mucus produced in airway passages.
Cystic fibrosis study offers new understanding of silent changes in genes
Researchers studying the root cause of cystic fibrosis have made a major advance in our understanding of silent gene changes with implications for the complexity of cystic fibrosis.
New imaging technique shows effectiveness of cystic fibrosis drug
Cystic fibrosis currently has no cure, though a drug approved by the Food and Drug Administration treats the underlying cause of the disease.
New study resolves the structure of the human protein that causes cystic fibrosis
In order to better understand how genetic mutations give rise to cystic fibrosis, researchers need to map the protein responsible for the disorder.
New molecules identified that could help in the fight to prevent cystic fibrosis
New research has identified new molecules that could help in the fight to prevent diseases caused by faulty ion channels, such as cystic fibrosis.
Newborn screening for cystic fibrosis
A new study led by a team from the Research Institute of the McGill University Health Centre and Cystic Fibrosis Canada reinforces the benefits of newborn screening for cystic fibrosis (CF) patients.
Evolving insights into cystic fibrosis lung infections
Recent research progress into how bacteria adapt and evolve during chronic lung infections in cystic fibrosis patients could lead to better treatment strategies being developed, according to a new review by the University of Liverpool.
Key hurdle overcome in the development of a drug against cystic fibrosis
In people suffering from cystic fibrosis the CFTR protein is not located in the right place in mucus-producing cells: it remains inside the cell while it should be in the cell wall.
Researchers further illuminate pathway for treatment of cystic fibrosis
By studying alveolar macrophages, which provide our airways with a crucial defense against pathogens, UNC scientists are now able to more fully understand the larger picture of CF symptoms and continue progress towards targeted treatments, aside from addressing the mutated CFTR gene.
Gene therapy: A promising candidate for cystic fibrosis treatment
An improved gene therapy treatment can cure mice with cystic fibrosis (CF).

Related Cystic Fibrosis Reading:

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Digital Manipulation
Technology has reshaped our lives in amazing ways. But at what cost? This hour, TED speakers reveal how what we see, read, believe — even how we vote — can be manipulated by the technology we use. Guests include journalist Carole Cadwalladr, consumer advocate Finn Myrstad, writer and marketing professor Scott Galloway, behavioral designer Nir Eyal, and computer graphics researcher Doug Roble.
Now Playing: Science for the People

#530 Why Aren't We Dead Yet?
We only notice our immune systems when they aren't working properly, or when they're under attack. How does our immune system understand what bits of us are us, and what bits are invading germs and viruses? How different are human immune systems from the immune systems of other creatures? And is the immune system so often the target of sketchy medical advice? Those questions and more, this week in our conversation with author Idan Ben-Barak about his book "Why Aren't We Dead Yet?: The Survivor’s Guide to the Immune System".